4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮 | 142328-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮
• 中文别名: 4,5,6,7-四氢-2,1,3-苯并二恶唑-4-酮
• 英文名称: 4-oxo-4,5,6,7-tetrahydrobenzofurazan
• 英文别名: 6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-one；4-oxo-4,5,6,7-tetrahydro-[2,1,3]benzoxadiazole；4,5,6,7-tetrahydro-2,1,3-benzoxadiazole-4-one；6,7-Dihydro-2,1,3-benzoxadiazol-4(5H)-one；6,7-dihydro-5H-2,1,3-benzoxadiazol-4-one
• CAS: 142328-06-1
• 化学式: C₆H₆N₂O₂
• mdl: MFCD00168434
• 分子量: 138.126
• InChiKey: YONIOJQXOFZEDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮 在 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以66%的产率得到4-oxo-5-hydroxyimino-4,5,6,7-tetrahydrobenzofurazan
  参考文献：
  名称：

  苯并二呋喃，苯并二呋喃和苯并呋喃氮杂呋喃的4,5'-二氢衍生物的合成

  摘要：

  DOI：

  10.1007/bf00486813
• 作为产物：
  描述：

  3-benzyloxy 2-chloropyridine 在 palladium on activated charcoal 、 氢气 、 potassium carbonate 、 戴斯-马丁氧化剂 、 肼 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 为溶剂， 25.0~160.0 ℃ 、101.33 kPa 条件下， 生成 4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮
  参考文献：
  名称：

  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors

  摘要：

  A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated in vivo, which enabled evaluation of TDO as a potential cancer immunotherapy target. As means of mitigating the risk of drug-drug interactions arising from cytochrome P450 inhibition, a novel property-based drug design parameter, herein referred to as the CYP Index, was implemented for the design of inhibitors with appreciable selectivity for TDO over CYP3A4. We anticipate the CYP Index will be a valuable design parameter for optimizing CYP inhibition of any small molecule inhibitor containing a Lewis basic motif capable of binding heme.

  DOI：

  10.1021/acsmedchemlett.0c00004

文献信息

• HMG-CoA reductase inhibitors
  申请人：Stein Philip D.

  公开号：US20070249583A1

  公开（公告）日：2007-10-25

  Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein A is chosen from B is chosen from wherein the variables R 1 to R 7 , m, n, are as defined herein. A method for treating the above diseases employing the above compounds is also provided.

  提供以下结构的化合物是HMG CoA还原酶抑制剂，因此在抑制胆固醇生物合成、调节血清脂质，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂蛋白血症和血脂异常、高胆固醇血症、高甘油三酯血症和动脉粥样硬化方面具有活性。 其中A选择自 B选择自 其中变量R1至R7，m，n， 如本文所定义。 还提供了一种利用上述化合物治疗上述疾病的方法。
• [EN] TDO2 INHIBITORS<br/>[FR] INHIBITEURS DE TDO2
  申请人：GENENTECH INC

  公开号：WO2017107979A1

  公开（公告）日：2017-06-29

  Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

  目前提供了细胞表达的TDO2的抑制剂及其药物组合物，用于调节色氨酸2,3双氧酶的活性；治疗免疫抑制；治疗受益于色氨酸降解抑制的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；以及治疗与癌症相关的肿瘤特异性免疫抑制。
• Compositions useful as inhibitors of protein kinases
  申请人：Jimenez Juan-Miguel

  公开号：US20050148603A1

  公开（公告）日：2005-07-07

  The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为蛋白激酶抑制剂有用的化合物。该发明还提供了制备这些化合物的方法，包括这些化合物的药用可接受组合物，以及在治疗各种疾病、症状或障碍中使用这些化合物和组合物的方法。
• Semmler-Wolff aromatization of 4-hydroxyimino-4,5,6,7-tetrahydro-[2,1,3]benzoxadiazole and 4-hydroxyimino-4,5,6,7-tetrahydro[2,1,3]benzoxadiazole 1-oxide and some properties of the obtained amines
  作者：V. A. Samsonov、G. E. Salʼnikov、L. B. Volodarskii

  DOI：10.1007/s10593-010-0596-9

  日期：2010.11

  The Semmler-Wolff aromatization of 4-hydroxyimino-4,5,6,7-tetrahydro[2,1,3]benzoxadiazole and its 1-oxide derivative in sulfuric acid and in acetic anhydride gave 4-amino[2,1,3]benzoxadiazole and 4-acetamido[2,1,3]benzoxadiazole 1-oxide. Some reactions of the resultant amines were studied.

  在硫酸和乙酸酐中将4-羟基亚氨基-4,5,6,7-四氢[2,1,3]苯并恶二唑及其1-氧化物衍生物进行Semmler-Wolff芳构化，得到4-氨基[2,1,3 ]苯并二唑和4-乙酰氨基[2,1,3]苯并二唑1-氧化物。研究了所得胺的一些反应。
• IL-12 modulatory compounds
  申请人：Demko Zachary

  公开号：US20060281711A1

  公开（公告）日：2006-12-14

  The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.

  本发明涉及环状腙类化合物、包括环状腙类化合物的组合物以及使用和制备这些组合物的方法。这些化合物（和组合物）在调节IL-12产生和通过IL-12介导的过程中是有用的。